-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027

Benzinga·10/19/2026 10:10:05

– Reuters